A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)

Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
10/2002
10/24/2002	WO2002083060A2 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	WO2002083059A2 Use of esters of long-chain fatty acids for treatment of autoimmune diseases
10/24/2002	WO2002083058A2 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
10/24/2002	WO2002074763A9 Benzimidazol derivatives modulate chemokine receptors
10/24/2002	WO2002061998A3 Access parameter adaptation and packet data resource management using detailed mobile status information
10/24/2002	WO2002060931A3 A fimbria-like gene in bifidobacteria
10/24/2002	WO2002051848A3 Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
10/24/2002	WO2002050065A3 Pyrazole compounds useful as protein kinase inhibitors
10/24/2002	WO2002047667A3 Novel medicament compositions based on anticholinesterase drugs and on a steroid
10/24/2002	WO2002040038A3 M. tuberculosis chaperonin 10 and uses thereof
10/24/2002	WO2002026258A3 Treatment of immune-mediated diseases by oral administration of plasma fractions
10/24/2002	WO2002024659A3 Substituted imidazoles as dual histamine h1 and h3 agonists or antgonists
10/24/2002	WO2001077375A8 Diagnosis of diseases associated with gene regulation
10/24/2002	WO2001076568B1 Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
10/24/2002	WO2001062793A9 Estrogen receptor beta variants and methods of detection thereof
10/24/2002	WO2001060778A9 Aspirin-triggered lipid mediators
10/24/2002	WO2001055337A3 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides
10/24/2002	US20020156292 Anticancer agents
10/24/2002	US20020156264 And method of using the carboxypeptidase polypeptides and polynucleotides as a target for diagnosis and treatment in carboxypeptidase-related disorders
10/24/2002	US20020156254 Nucleotide sequences coding polypeptide for use in the treatment of stress, diabetes, cancer, inflammatory and cardiovascular disorders
10/24/2002	US20020156133 Oral administration forms for administering a fixed tramadol and diclofenac combination
10/24/2002	US20020156127 Carbamate compounds for use in the treatment of pain
10/24/2002	US20020156124 Paclitaxel, a solvent, a surfactant, a substituted cellulosic polymer, and a P-glycoprotein inhibitor; supersaturation of a microemulsion upon contact with water
10/24/2002	US20020156122 Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent
10/24/2002	US20020156111 Substituted bicyclic compounds
10/24/2002	US20020156104 Novel pyrazole and pyrazoline substituted compounds
10/24/2002	US20020156102 Piperidine amides as modulators of chemo kine receptor activity
10/24/2002	US20020156094 Sulfonamide interleukin-1beta converting enzyme inhibitors
10/24/2002	US20020156092 Ligands for G-protein-coupled receptors and opiod receptors; analgesics, treating drug addiction, or tinnitus
10/24/2002	US20020156091 Dosing interval of the nimesulide overlaps with that of the oxycodone to reduce the amount of oxycodone needed to provide an effect
10/24/2002	US20020156081 Pyrazolopyrimidines as therapeutic agents
10/24/2002	US20020156074 Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors
10/24/2002	US20020156071 Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors
10/24/2002	US20020156069 Benzo thiadiazine matrix metalloproteinase inhibitors
10/24/2002	US20020156063 Heterocyclic amide compounds useful for treating diseases associated with activity of cathepsin K
10/24/2002	US20020156061 Administering to a mammal a matrix metalloproteinase inhibiting amount of derivatives of isophthalic acid, isophthalic acid ester or isothalamide compounds to treat cancer, rheumatic arthritis atherosclerosis and osteoporosis
10/24/2002	US20020156053 Treating gastro-oesophageal reflux disease
10/24/2002	US20020156050 Poly(adenosine 5'-diphospho-ribose) polymerase (PARP) inhibitors
10/24/2002	US20020156030 Heterocyclic aromatic compounds and uses thereof
10/24/2002	US20020156000 Inhibiting NF-kappa B-dependent target gene expression in a cell.
10/24/2002	US20020155997 Biologically active material isolated from non-pathogenic bacteria, such as Enterobacteriaceae
10/24/2002	US20020155609 Monocyte-specific particulate delivery vehicle
10/24/2002	US20020155545 Chemokines expressed in pancreas
10/24/2002	US20020155534 SBHWSB2: a new member of the WD40 SOCS box family
10/24/2002	US20020155528 Regulation of human CysLT2-like GPCR protein
10/24/2002	US20020155098 Methods for treating the inflammatory component of a brain disorder
10/24/2002	DE10119905A1 Enriching intermediates in the mevalonate-independent pathway of isoprenoid synthesis, useful for therapeutic activation of T cells, comprises altering enzymatic activity in the pathway
10/24/2002	DE10119804A1 New peptides produced in primates during inflammation and sepsis, useful for diagnosis and treatment of these diseases, and their related antibodies
10/24/2002	CA2490819A1 Compounds useful as anti-inflammatory agents
10/24/2002	CA2455274A1 Animal model for evaluating analgesics
10/24/2002	CA2445538A1 Oxalic acid derivatives
10/24/2002	CA2444761A1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations
10/24/2002	CA2444632A1 Vascular endothelial growth factor 2
10/24/2002	CA2444548A1 Methods of diagnosing and treating small intestinal bacterial overgrowth (sibo) and sibo-related conditions
10/24/2002	CA2444518A1 Biomaterials comprising a melanocyte stimulating hormone (msh), and method of forming
10/24/2002	CA2444267A1 Prodrugs of cox-2 inhibitors
10/24/2002	CA2444247A1 Inhibitors of integrin .alpha.v.beta.6
10/24/2002	CA2444220A1 Orally deliverable pharmaceutical composition comprising a drug of low water solubility (cox-2 inhibitor), a solvent, a fatty acid and an organic amine
10/24/2002	CA2444164A1 Pufa polyketide synthase systems and uses thereof
10/24/2002	CA2443995A1 Endothelial cell expression patterns
10/24/2002	CA2443903A1 Antibodies to vla-1
10/24/2002	CA2443777A1 Therapeutic and diagnostic uses of antibody specificity profiles
10/24/2002	CA2443732A1 Use of amino acid transporter atb0,+ as a delivery system for drugs and prodrugs
10/24/2002	CA2443709A1 Novel cyclo azaphospha hydrocarbons
10/24/2002	CA2443699A1 Phenyl heterocyclyl ether
10/24/2002	CA2443487A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/24/2002	CA2443468A1 Pharmaceutical product with reticulated crystalline microstructure
10/24/2002	CA2443244A1 Enzymes
10/24/2002	CA2443234A1 Isoxaxole derivatives as inhibitors of src and other protein kinases
10/24/2002	CA2442953A1 Fatty alcohols and fatty acid esters useful for treatment of inflammation
10/24/2002	CA2442943A1 Anti-inflammatory fatty alcohols and fatty acid esters useful as antigen carriers
10/24/2002	CA2440842A1 Novel 1h-indazole compounds
10/24/2002	CA2431553A1 Cxcr3 antagonists
10/23/2002	EP1251177A2 Cytokine-, stress-, and oncoprotein-activited human protein kinase kinases
10/23/2002	EP1251170A2 Method and reagent for treatment of NF-kappaB dependent animal diseases
10/23/2002	EP1251128A1 Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists
10/23/2002	EP1250922A1 Rolled external-use patch
10/23/2002	EP1250920A1 Unloaded ion exchange resins for the extended release of active ingredients
10/23/2002	EP1250331A1 Formulation for protection against oxidative stress containing benzofuranone derivatives
10/23/2002	EP1250325A1 Phenanthridine-n-oxides
10/23/2002	EP1250317A2 Bis-basic compounds for use as tryptase inhibitors, method for producing the same and their use as medicaments
10/23/2002	EP1250313A1 Monohydrate of cis-lithium-cyano-4- 3-(cyclopentyloxy)-4-methoxyphenyl]cyclohexanecarboxylate
10/23/2002	EP1250155A1 Angiogenesis and vascular permeability modulators and inhibitors
10/23/2002	EP1250142A1 Multivalent electron active compositions and methods of making and using same
10/23/2002	EP1250137A2 Jak/stat pathway inhibitors and the uses thereof
10/23/2002	EP1250132A1 Ibuprofen containing active agent preparation
10/23/2002	EP1250116A1 Pharmaceutical and cosmetic carrier or composition for topical application
10/23/2002	EP1250055A1 Immune modulation with death receptor-induced apoptosis
10/23/2002	EP1250045A2 Particulate blends and compacted products formed therefrom, and the preparation thereof
10/23/2002	EP0925303B1 Phosphinic acid amides as matrix metalloprotease inhibitors
10/23/2002	EP0869947B1 Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds
10/23/2002	EP0826000B1 Peptide compounds which inhibit metalloproteinase and tnf liberation and their therapeutic uses
10/23/2002	EP0783499B1 Benzofuran derivatives as tachykinin antagonists
10/23/2002	EP0723552B1 Oligopeptides derived from c-reactive protein fragments
10/23/2002	CN1376157A Triazolopurine derivatives, drug compositions containing the same and adenosine A3 receptor affinitive agents
10/23/2002	CN1376156A Benzodiazepin derivatives, the production and use thereof
10/23/2002	CN1376146A Solid-state form of celecoxil having enhanced bioavailability
10/23/2002	CN1376144A Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
10/23/2002	CN1376143A Carboxylic acid derivatives and adhesion molecule inhibitors containing the same as the active ingredient
10/23/2002	CN1376065A Compositions having improved stability

1 ... 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 ... 1272